Section Arrow
RAPT.NASDAQ
- RAPT Therapeutics Inc
Quotes are at least 15-min delayed:2025/07/21 08:31 EDT
Pre Market
Last
 11.09
-0.59 (-5.05%)
Bid
11.09
Ask
11.68
High 11.99 
Low 11.09 
Volume 458 
Regular Hours
Last
 11.68
+1.45 (+14.17%)
Day High 
12 
Prev. Close
10.23 
1-M High
11.94 
Volume 
163.06K 
Bid
11.09
Ask
11.68
Day Low
10.35 
Open
10.35 
1-M Low
6.88 
Market Cap 
169.16M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 8.98 
20-SMA 8.57 
50-SMA 8.01 
52-W High 27.84 
52-W Low 5.6652 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-19.84/-2.77
Enterprise Value
171.23M
Balance Sheet
Book Value Per Share
10.73
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 2.04 -0.24 -10.53%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 12.854 -1.221 -8.67%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0559 +0.0082 +17.19%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.17 +0.33 +5.65%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.28 +0.36 +6.08%
Quotes are at least 15-min delayed:2025/07/21 08:31 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cellsinto inflamed tissues.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.